Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD

Anthony D'Urzo; Kenneth R Chapman; James F Donohue; Peter Kardos; M Reza Maleki-Yazdi; David Price

doi:10.1007/s41030-019-0090-1

Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD

Anthony D'Urzo^*, Kenneth R Chapman, James F Donohue, Peter Kardos, M Reza Maleki-Yazdi, David Price

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

3 Citations (Scopus)

8 Downloads (Pure)

Abstract

Inhaled fixed-dose combinations (FDCs) of a long-acting β-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) have become the cornerstone for the maintenance treatment of symptomatic COPD patients. In this regard, global COPD treatment guidelines have recognized the importance of inhaler devices as integral contributors to the effectiveness of LABA/LAMA FDCs and recommend regular assessment of inhaler device use by the patients in order to improve long-term clinical outcomes. Optimal disease control is also highly dependent upon patient preferences and adherence to inhaler devices. This review objectively examines and compares the major inhaler devices used to deliver different LABA/LAMA FDCs, discusses the inhaler device characteristics that determine drug deposition in the airways, real-life preference for inhaler devices, and handling of inhaler devices that impact the results of the long-term management of COPD. The introduction of new LABA/LAMA FDCs, new inhaler devices, and more clinical studies have created confusion among physicians in choosing the optimal inhaled therapy for COPD patients; in this context, this review attempts to provide an evidence-based framework for informed decision-making with a particular focus on the inhaler devices.Funding. The preparation of this manuscript was funded by Novartis Pharma AG.

Original language	English
Pages (from-to)	23-41
Number of pages	19
Journal	Pulmonary Therapy
Volume	5
Early online date	13 Mar 2019
DOIs	https://doi.org/10.1007/s41030-019-0090-1
Publication status	Published - 2019

Bibliographical note

Published 13th March 2019. Issue Date June 2019.

Funding. The preparation of this manuscript was funded by Novartis Pharma AG. No funding or sponsorship was recieved for the publication of this article.

Medical Writing and Editorial Assistance
The authors thank David Prefontaine, PhD and Rahul Lad, PhD (Novartis), and Praveen Kaul, PhD for providing medical writing and editorial support, which was funded by Novartis Pharma AG in accordance with Good Publication Practice (GPP3) guidelines.

Keywords

Bronchodilation
Chronic obstructive pulmonary disease
Combination bronchodilator agents
Inhalers
LABA
LAMA
Pharmacotherapy

Access to Document

10.1007/s41030-019-0090-1Licence: CC BY

Price_InhalerDevicesForDelivery_VOR
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Final published version, 752 KBLicence: CC BY

Cite this

@article{d38c92d609e545a394c912ad3272d0df,

title = "Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD",

abstract = "Inhaled fixed-dose combinations (FDCs) of a long-acting β-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) have become the cornerstone for the maintenance treatment of symptomatic COPD patients. In this regard, global COPD treatment guidelines have recognized the importance of inhaler devices as integral contributors to the effectiveness of LABA/LAMA FDCs and recommend regular assessment of inhaler device use by the patients in order to improve long-term clinical outcomes. Optimal disease control is also highly dependent upon patient preferences and adherence to inhaler devices. This review objectively examines and compares the major inhaler devices used to deliver different LABA/LAMA FDCs, discusses the inhaler device characteristics that determine drug deposition in the airways, real-life preference for inhaler devices, and handling of inhaler devices that impact the results of the long-term management of COPD. The introduction of new LABA/LAMA FDCs, new inhaler devices, and more clinical studies have created confusion among physicians in choosing the optimal inhaled therapy for COPD patients; in this context, this review attempts to provide an evidence-based framework for informed decision-making with a particular focus on the inhaler devices.Funding. The preparation of this manuscript was funded by Novartis Pharma AG.",

keywords = "Bronchodilation, Chronic obstructive pulmonary disease, Combination bronchodilator agents, Inhalers, LABA, LAMA, Pharmacotherapy",

author = "Anthony D'Urzo and Chapman, {Kenneth R} and Donohue, {James F} and Peter Kardos and Maleki-Yazdi, {M Reza} and David Price",

note = "Published 13th March 2019. Issue Date June 2019. Funding. The preparation of this manuscript was funded by Novartis Pharma AG. No funding or sponsorship was recieved for the publication of this article. Medical Writing and Editorial Assistance The authors thank David Prefontaine, PhD and Rahul Lad, PhD (Novartis), and Praveen Kaul, PhD for providing medical writing and editorial support, which was funded by Novartis Pharma AG in accordance with Good Publication Practice (GPP3) guidelines.",

year = "2019",

doi = "10.1007/s41030-019-0090-1",

language = "English",

volume = "5",

pages = "23--41",

journal = "Pulmonary Therapy",

issn = "2364-1746",

publisher = "Springer ",

}

TY - JOUR

T1 - Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD

AU - D'Urzo, Anthony

AU - Chapman, Kenneth R

AU - Donohue, James F

AU - Kardos, Peter

AU - Maleki-Yazdi, M Reza

AU - Price, David

N1 - Published 13th March 2019. Issue Date June 2019. Funding. The preparation of this manuscript was funded by Novartis Pharma AG. No funding or sponsorship was recieved for the publication of this article. Medical Writing and Editorial Assistance The authors thank David Prefontaine, PhD and Rahul Lad, PhD (Novartis), and Praveen Kaul, PhD for providing medical writing and editorial support, which was funded by Novartis Pharma AG in accordance with Good Publication Practice (GPP3) guidelines.

PY - 2019

Y1 - 2019

N2 - Inhaled fixed-dose combinations (FDCs) of a long-acting β-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) have become the cornerstone for the maintenance treatment of symptomatic COPD patients. In this regard, global COPD treatment guidelines have recognized the importance of inhaler devices as integral contributors to the effectiveness of LABA/LAMA FDCs and recommend regular assessment of inhaler device use by the patients in order to improve long-term clinical outcomes. Optimal disease control is also highly dependent upon patient preferences and adherence to inhaler devices. This review objectively examines and compares the major inhaler devices used to deliver different LABA/LAMA FDCs, discusses the inhaler device characteristics that determine drug deposition in the airways, real-life preference for inhaler devices, and handling of inhaler devices that impact the results of the long-term management of COPD. The introduction of new LABA/LAMA FDCs, new inhaler devices, and more clinical studies have created confusion among physicians in choosing the optimal inhaled therapy for COPD patients; in this context, this review attempts to provide an evidence-based framework for informed decision-making with a particular focus on the inhaler devices.Funding. The preparation of this manuscript was funded by Novartis Pharma AG.

AB - Inhaled fixed-dose combinations (FDCs) of a long-acting β-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) have become the cornerstone for the maintenance treatment of symptomatic COPD patients. In this regard, global COPD treatment guidelines have recognized the importance of inhaler devices as integral contributors to the effectiveness of LABA/LAMA FDCs and recommend regular assessment of inhaler device use by the patients in order to improve long-term clinical outcomes. Optimal disease control is also highly dependent upon patient preferences and adherence to inhaler devices. This review objectively examines and compares the major inhaler devices used to deliver different LABA/LAMA FDCs, discusses the inhaler device characteristics that determine drug deposition in the airways, real-life preference for inhaler devices, and handling of inhaler devices that impact the results of the long-term management of COPD. The introduction of new LABA/LAMA FDCs, new inhaler devices, and more clinical studies have created confusion among physicians in choosing the optimal inhaled therapy for COPD patients; in this context, this review attempts to provide an evidence-based framework for informed decision-making with a particular focus on the inhaler devices.Funding. The preparation of this manuscript was funded by Novartis Pharma AG.

KW - Bronchodilation

KW - Chronic obstructive pulmonary disease

KW - Combination bronchodilator agents

KW - Inhalers

KW - LABA

KW - LAMA

KW - Pharmacotherapy

U2 - 10.1007/s41030-019-0090-1

DO - 10.1007/s41030-019-0090-1

M3 - Review article

C2 - 32026426

SN - 2364-1746

VL - 5

SP - 23

EP - 41

JO - Pulmonary Therapy

JF - Pulmonary Therapy

ER -

Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this